| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
Prim-O-glucosylcimifugin is a natural product acting as a potent inhibitor of iNOS and COX-2 and shows anti-inflammatory effects by through regulating JAK2/STAT3 signaling.
| ln Vitro |
Prim-O-glucosylcimifugin (POG) is the most abundant chromone and one of the most active components in Radix Saposhnikoviae (RS). Prim-O-glucosylcimifugin reduces inflammation in RAW 264.7 macrophages by reducing iNOS and COX-2 production via the JAK2/STAT3 signaling pathway. Prim-O-glucosylcimifugin's cytotoxicity is assessed against LPS-activated Raw 264.7 macrophages. Raw 264.7 macrophages were treated with LPS (1 μg/mL) and escalating doses of Prim-O-glucosylcimifugin (15, 50, and 100 μg/mL) for 24 hours. Cell viability was assessed using the CCK-8 test. After 24 hours of exposure to 15-100 μg/mL Prim-O-glucosylcimifugin, cell viability did not significantly differ from that of DMSO-treated cells (control). Prim-O-glucosylcimifugin's anti-inflammatory impact is investigated by examining its ability to alter NO production in LPS-activated RAW 264.7 cells. Macrophages were treated with LPS (1 μg/mL) with different doses of Prim-O-glucosylcimifugin (15, 50, and 100 μg/mL) during 24 hours. Griess reaction does not assess quantities in culture supernatants. LPS exposure causes a considerable increase in NO concentrations in culture supernatants, while Prim-O-glucosylcimifugin blocks LPS-induced NO generation in a concentration-dependent manner[1].
|
|---|---|
| ln Vivo |
When lipopolysaccharide (LPS) is administered, bronchoalveolar lavage fluid (BALF) is obtained seven hours later, and the cytokine levels in BALF are assessed using ELISA. TNF-α, IL-1β, and IL-6 levels in BALF are significantly higher than those in the control group. On the other hand, pretreatment with 2.5, 5 or 10 mg/kg of Prime-O-glucosylcimifugin significantly reduces TNF-α, IL-1β, and IL-6 levels in a dose-dependent manner (P<0.05, P<0.01)[1].
|
| References | |
| Additional Infomation |
PRIM-O-GLUCOSYLCIMIFUGIN is an organic heterotricyclic compound and an oxacycle.
Prim-O-glucosylcimifugin has been reported in Angelica japonica, Eranthis hyemalis, and other organisms with data available. |
| Molecular Formula |
C22H28O11
|
|---|---|
| Molecular Weight |
468.45112
|
| Exact Mass |
468.163
|
| CAS # |
80681-45-4
|
| PubChem CID |
14034912
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
736.9±60.0 °C at 760 mmHg
|
| Melting Point |
120 °C
|
| Flash Point |
255.0±26.4 °C
|
| Vapour Pressure |
0.0±2.5 mmHg at 25°C
|
| Index of Refraction |
1.648
|
| LogP |
-1.35
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
33
|
| Complexity |
755
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC(C)([C@@H]1CC2=C(O1)C=C3C(=C2OC)C(=O)C=C(O3)CO[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O
|
| InChi Key |
XIUVHOSBSDYXRG-UVTAEQIVSA-N
|
| InChi Code |
InChI=1S/C22H28O11/c1-22(2,28)15-5-10-12(32-15)6-13-16(20(10)29-3)11(24)4-9(31-13)8-30-21-19(27)18(26)17(25)14(7-23)33-21/h4,6,14-15,17-19,21,23,25-28H,5,7-8H2,1-3H3/t14-,15+,17-,18+,19-,21-/m1/s1
|
| Chemical Name |
(2S)-2-(2-hydroxypropan-2-yl)-4-methoxy-7-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-2,3-dihydrofuro[3,2-g]chromen-5-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 150 mg/mL (~320.20 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (4.44 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1347 mL | 10.6735 mL | 21.3470 mL | |
| 5 mM | 0.4269 mL | 2.1347 mL | 4.2694 mL | |
| 10 mM | 0.2135 mL | 1.0673 mL | 2.1347 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
